Soleno Therapeutics Inc.
Soleno Therapeutics Announces Preliminary Q4 and Full-Year 2025 Financial Results
Summary
Soleno Therapeutics, Inc. announced preliminary financial results for the year and fourth quarter of 2025. Expected full-year net revenue is between $189 million to $191 million, and fourth quarter net revenue is expected to be between $90 million to $92 million. The company reported a total of 1,250 new patient start forms, with 630 unique prescribers, and over 185 million lives covered. Soleno also highlighted achieving profitability and positive cash flow with year-end cash, cash equivalents, and marketable securities of approximately $500 million.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement